We are live on
!
Find out more
IMUC
ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC
Delisted
IMUC was delisted on the 16th of October, 2018.
23 hedge funds and large institutions have $601K invested in ImmunoCellular Therapeutics, Ltd. in 2018 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
105% more capital invested
Capital invested by funds: $293K → $601K (+$308K)
35% more funds holding
Funds holding: 17 → 23 (+6)
Holders
23
Holders Change
+6
Holders Change %
+35.29%
% of All Funds
0.53%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
3
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$119K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$109K |
| 3 |
Millennium Management
New York
|
+$104K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$22K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$18.3K |
Top Sellers
| 1 |
Goldman Sachs
New York
|
-$8K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$3K |
